Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance

Leukemia volume 16, pages 1870–1871 (2002)Cite this article

Treatment of relapsed AML is difficult, especially if remission duration was short, if it is later than first relapse, if karyotype is unfavourable or if the patient is not eligible for intensive treatment. We report a case of a 76-year-old female patient presenting with all these unfavourable predictors. Remarkably, this patient entered a third complete remission (CR) following a single dose of gemtuzumab ozogamicin (CMA-676), and CR duration with low-dose interleukin-2 (IL-2) maintenance now exceeds 11 months.

The patient was first diagnosed with AML, FAB M5, with t(1;21)(q21;q22) in October 1998. The patient was treated with cytarabine, daunorubicin and the multidrug resistance modulator PSC 833 for induction resulting in CR, followed by two consolidation chemotherapies which consisted of cytarabine, daunorubicin and PSC 833 (consolidation 1), and cytarabine, mitoxantrone and etoposide (consolidation 2). Treatment was complicated by profuse peranal bleeding during pancytopenia following induction.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Denzlinger C, Bowen D, Benz D, Gelly K, Brugger W, Kanz L . Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia Br J Haematol 2000 108: 93–95

    Article  CAS  PubMed  Google Scholar 

  2. Sievers EL, Linenberger M . Mylotarg: antibody-targeted chemotherapy comes of age Curr Opin Oncol 2001 13: 522–527

    Article  CAS  PubMed  Google Scholar 

  3. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID . Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 immunoconjugate Blood 1999 93: 3678–3684

    CAS  PubMed  Google Scholar 

  4. Griffin JD, Linch D, Sabbath K, Larcom P, Schlossman SF . A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells Leuk Res 1984 8: 521–534

    Article  CAS  PubMed  Google Scholar 

  5. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR . Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse J Clin Oncol 2001 9: 3244–3254

    Article  Google Scholar 

  6. Adler A, Chervenick PA, Whiteside TL, Lotzova E, Herberman RB . Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission Blood 1988 71: 709–716

    CAS  PubMed  Google Scholar 

  7. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos AG, Mandelli F . Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia Blood 1994 84: 2158–2163

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology/Oncology, University of Tübingen, Medical School, Tübingen, Germany

    MP Radsak, HR Salih, M Sökler, L Kanz & C Denzlinger

Authors
  1. MP Radsak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. HR Salih
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Sökler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Kanz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Denzlinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Radsak, M., Salih, H., Sökler, M. et al. Sustained complete remission of recurrent acute myeloid leukaemia with a single dose of gemtuzumab ozogamicin and low-dose interleukin-2 maintenance. Leukemia 16, 1870–1871 (2002). https://doi.org/10.1038/sj.leu.2402594

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402594

Search

Advanced search

Quick links